The Oncology InstituteTOIIW 56 EBIT per Share is $0.00 as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 530 Healthcare Providers & Services companies, The Oncology Institute ranks better than 66.42% on this metric.
The Oncology Institute's EBIT per Share for the
three
months ended in Mar. 2026 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 24.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -18.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for The Oncology Institute's EBIT per Share or its related term are showing as below:
TOIIW'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -179.3 Med: -45.45 Max: 24.1
Current: 24.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of The Oncology Institute was 24.10% per year. The lowest was -179.30% per year. And the median was -45.45% per year.
TOIIW's 3-Year EBIT Growth Rate is ranked better than 66.42% of 530
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs TOIIW: 24.10
The Oncology Institute (NAS:TOIIW) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
The Oncology Institute EBIT per Share Related Terms
The Oncology Institute EBIT per Share Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOIIW) has a EBIT per Share of $0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #178 out of 530 companies in the Healthcare Providers & Services industry, placing it in the top 33.6%.
Is The Oncology Institute's EBIT per Share too high?
The Oncology Institute's current EBIT per Share is $0.00. Based on the distribution chart, The Oncology Institute ranks #178 out of 530 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's EBIT per Share compare to CCRN and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #178 out of 530 companies for EBIT per Share. This puts The Oncology Institute in the upper half of its industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 530 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current EBIT per Share of $0.00. The current EBIT per Share is $0.00. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current EBIT per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
